Screening Strategy for Gastric Cancer Prevention

Status Not yet recruiting

Clinical Trial Summary

There are still some unsolved questions regarding population-based screening program for H. pylori infection to prevent gastric cancer, such as how to perform the optimal screening strategies. A prospective, randomized trial will be conducted to compare the acceptability, compliance (/adherence), and accuracy of diagnostic tests in a population-based H. pylori screening and gastric cancer prevention program. The investigators will recruit 10,000 adults with age of ≥20 years who have not received H. pylori screening or treatment. Eligible patients will be randomly 1:1:1:1 allocated to four groups with different combination tests.

Clinical Trial Description

Background: There are still some unsolved questions regarding population-based screening program for H. pylori infection to prevent gastric cancer, such as how to perform the optimal screening strategies. Objective: A prospective, randomized trial will be conducted to compare the acceptability, compliance (/adherence), and accuracy of C13 UBT and HpSA in a population-based H. pylori screening and gastric cancer prevention program. Methods：Open labeled, randomized controlled trial The investigators will recruit 10,000 adults with age of ≥20 years who have not received H. pylori screening or treatment. Eligible patients will be randomly 1:1:1:1 allocated to (A) The carbon-13 urea breath test (C13 UBT), (B) H. pylori stool antigen test (Vstrip® HpSA), (C) Both C13 UBT and HpSA, (D) Two-stage screening method (serology screening only, and then C13 UBT for confirmation if serology test is positive). Outcome analysis: 1. Detection rate of H. pylori infection 2. To compare the compliance(/adherence) of screening tests for H. pylori infection in the two randomized groups. 3. To assess the diagnostic accuracy of these tests. 4. To verify the compliance(/adherence) and feasibility of this two-stage screening method 5. Long-term Outcomes: To assess the risk reduction of gastric cancer ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05387005
Study type	Interventional
Source	National Taiwan University Hospital
Contact	Jyh-Ming Liou, MD,PhD
Phone	886-2-23123456
Email	jyhmingliou@gmail.com
Status	Not yet recruiting
Phase	N/A
Start date	May 30, 2022
Completion date	March 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06045494` - The Efficacy of Treatment for Helicobacter Pylori Infection in Preschooler by Yoghurt With LG21	N/A
Not yet recruiting	`NCT01449500` - Supplementation With L. Reuteri in H. Pylori Infected Adults	N/A
Completed	`NCT01234389` - Immediate Detection of Helicobacter Infection With a New Electrochemical System.	N/A
Not yet recruiting	`NCT02761005` - Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori	Phase 2
Recruiting	`NCT03142620` - Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study	Phase 3
Withdrawn	`NCT02090738` - A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide	Phase 2
Recruiting	`NCT01335334` - H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study	Phase 4
Recruiting	`NCT05544396` - Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis.	N/A
Recruiting	`NCT04713670` - Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection	Phase 4
Recruiting	`NCT06045832` - Oral Helicobacter Pylori Eradication	N/A
Completed	`NCT05453994` - Bismuth for PCAB-based H. Pylori Eradication
Recruiting	`NCT02328131` - European Registry on the Management of Helicobacter Pylori Infection
Completed	`NCT00197457` - Pepsinogens as the Early Marker of H. Pylori Eradication	Phase 2
Not yet recruiting	`NCT06412640` - Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori	Phase 4
Completed	`NCT04036838` - ARJ C13 Urea Breath Test System	Phase 2
Completed	`NCT06050824` - A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection	Phase 4
Completed	`NCT02767479` - Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori	Phase 3
Completed	`NCT01505127` - Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori	Phase 3
Recruiting	`NCT05176821` - Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection	N/A
Completed	`NCT05002595` - H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.